Cumberland Pharmaceuticals (NASDAQ:CPIX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Monday.

Cumberland Pharmaceuticals (NASDAQ CPIX) traded down $0.29 during midday trading on Monday, reaching $7.31. The company’s stock had a trading volume of 13,172 shares, compared to its average volume of 18,305. The company has a current ratio of 4.18, a quick ratio of 3.81 and a debt-to-equity ratio of 0.12. Cumberland Pharmaceuticals has a one year low of $5.16 and a one year high of $7.96.

Several institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its stake in shares of Cumberland Pharmaceuticals by 0.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 23,892 shares of the specialty pharmaceutical company’s stock valued at $167,000 after purchasing an additional 80 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Cumberland Pharmaceuticals by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 298,635 shares of the specialty pharmaceutical company’s stock valued at $2,111,000 after purchasing an additional 1,180 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Cumberland Pharmaceuticals by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 866,283 shares of the specialty pharmaceutical company’s stock valued at $6,125,000 after purchasing an additional 2,464 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Cumberland Pharmaceuticals by 5.2% in the 1st quarter. Renaissance Technologies LLC now owns 270,240 shares of the specialty pharmaceutical company’s stock valued at $1,875,000 after purchasing an additional 13,240 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its stake in shares of Cumberland Pharmaceuticals by 116.1% in the 3rd quarter. Essex Investment Management Co. LLC now owns 34,494 shares of the specialty pharmaceutical company’s stock valued at $244,000 after purchasing an additional 18,535 shares during the last quarter. 34.44% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/04/cumberland-pharmaceuticals-cpix-downgraded-to-sell-at-valuengine.html.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.